Modern preventive medications may have lowered recurrent stroke rates, suggesting future secondary prevention trials will require larger sample sizes.
Despite rigorous ascertainment, recurrent stroke rates were lower in current study than in earlier studies. Our data suggest that large sample sizes may be needed for future secondary prevention trials in patients treated with modern preventive medications.
Callaly et al. (Mon,) studied this question.